VBIV News and Press, VBI Vaccines Inc. From 09/15/22

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced it has entered into a refinanced and upsized debt facility of up to $100 million with its existing lender, K2 HealthVe...

French biotech Valneva SE ( VALN ) and U.S.-based VBI Vaccines ( NASDAQ: VBIV ) announced a partnership on Wednesday to jointly market and distribute the PreHevbri Hepatitis B vaccine in select European countries starting from early next year. The companies said that P...

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) (Valneva) and VBI Vaccines Inc. (Nasdaq: VBIV) (VBI) today announced a partnership in select European markets for the marketing and distribution of PreHevbri® [Hepatitis B vaccine (recombinant, adsorbed)], the only 3-antigen hepatitis ...

Shares of VBI Vaccines ( NASDAQ: VBIV ) declined 10% in Friday post-market trading after the company said it is terminating two "at the market" equity offerings with Jefferies and also filing for a mixed shelf offering. VBI ( VBIV ) shares initially shot up in ...

VBI Vaccines ( NASDAQ: VBIV ) stock fell ~10% premarket Aug. 8 after the company's Q2 revenues missed analysts estimates, and net loss widened. Q2 net loss increased to -$45.7M, compared to -$17.48M in Q2 2021. Meanwhile, net loss excluding foreign exchange loss ...

NuZee ( NUZE ) -24% on pricing $3.4M stock offering . Reata Pharmaceuticals ( RETA ) -20% on Q2 earnings release . Palantir Technologies ( PLTR ) -14% on Q2 earnings release . Digital World Acquisition ( DWACW ) -10% . Cognit...

VBI Vaccines press release ( NASDAQ: VBIV ): Q2 Non-GAAP EPS of -$0.09 misses by $0.02 . Revenue of $0.35M (+150.0% Y/Y) misses by $0.35M . Two new clinical studies in GBM patients expected to start before the end of 2022 In partnership with the Government ...

PreHevbrio™ [Hepatitis B Vaccine (Recombinant)] launched in the U.S. at the end of Q1 2022 – advancing through commercial stage gates required to enable broad access to the 3-antigen adult hepatitis B (HBV) vaccine FDA Orphan Drug Designation received for VBI-1901 fo...

The back half of 2022 is already shaping up to be a stock picker's market. Today's mixed trading session in the volatile healthcare sector is a case in point. For example, shares of the clinical-stage biotech Ocugen (NASDAQ: OCGN) were down by a hefty 9.5% and Sorrento Therape...

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that John Dillman has been appointed as the Company’s Chief Commercial Officer. Mr. Dillman will be respons...